2020 ADCES Diabetes Care and
Education Specialist of the Year
My Mission
To utilize the latest technology and innovations to improve the lives for people with diabetes
Bio
Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP is an Endocrinology Clinical Pharmacy Specialist. She serves as the Co-Director of Endocrine Disorders in Pregnancy and the Director of Education and Training in Diabetes Technology at the Cleveland Clinic Endocrinology and Metabolism Institute.
Dr. Isaacs holds board certifications in pharmacotherapy, ambulatory care, and advanced diabetes management. She served on the American Diabetes Association (ADA) Professional Practice Committee from 2020-2023, the committee that updates the ADA Standards of Care. She also was the ADA Communications Director for the Pregnancy and Reproductive Health Interest Group from 2018-2022. She has been actively involved with the American Association of Clinical Endocrinology (AACE) and currently serves on the leadership of the Diabetes Disease State Network.
She co-hosts a podcast titled “Diabetes Dialogue: Technology, Therapeutics and Real-World Perspectives.” She advocates access and choice to the latest technologies and therapeutics for all people with diabetes and speaks on diabetes related topics nationally and internationally. She was the ADCES Diabetes Care and Education Specialist of the Year in 2020 and inducted into the SIUE Alumni Hall of Fame in 2022 for her far-reaching contributions in diabetes care.


Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP is an Endocrinology Clinical Pharmacy Specialist. She is the Co-Director of Endocrine Disorders in Pregnancy at the Cleveland Clinic Endocrinology and Metabolism Institute. She is also the Director of Education & Training in Diabetes Technology.
Dr. Isaacs earned her bachelor’s degree in chemistry from the University of Illinois at Chicago, Doctor of Pharmacy Degree from Southern Illinois University Edwardsville (SIUE) and completed a pharmacy practice residency at the Philadelphia VA. Dr. Isaacs holds board certifications in pharmacotherapy, ambulatory care, and advanced diabetes management. She served on the American Diabetes
Association (ADA) Professional Practice Committee from 2020-2023, the committee that updates the ADA Standards of Care. She is currently a National Board Member of the Association of Diabetes Care and Education Specialists (ADCES).
She advocates access and choice to the latest technologies and therapeutics for all people with diabetes and speaks on diabetes related topics nationally and internationally. She was the ADCES Diabetes Care and Education Specialist of the Year in 2020 and inducted into the SIUE Hall of Fame in 2022 for her far reaching contributions in diabetes care.
Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP is an Endocrinology Clinical Pharmacy Specialist. She serves as the Co-Director of Endocrine Disorders in Pregnancy and the Director of Education and Training in Diabetes Technology at the Cleveland Clinic Endocrinology and Metabolism Institute.
Dr. Isaacs holds board certifications in pharmacotherapy, ambulatory care, and advanced diabetes management. She served on the American Diabetes Association (ADA) Professional Practice Committee from 2020-2023, the committee that updates the ADA Standards of Care. She also was the ADA Communications Director for the Pregnancy and Reproductive Health Interest Group from 2018-2022. She has been actively involved with the American Association of Clinical Endocrinology (AACE) and currently serves on the leadership of the Diabetes Disease State Network.
She co-hosts a podcast titled “Diabetes Dialogue: Technology, Therapeutics and Real-World Perspectives.” She advocates access and choice to the latest technologies and therapeutics for all people with diabetes and speaks on diabetes related topics nationally and internationally. She was the ADCES Diabetes Care and Education Specialist of the Year in 2020 and inducted into the SIUE Alumni Hall of Fame in 2022 for her far-reaching contributions in diabetes care.

Awards

- 2022 SIUE Alumni Hall of Fame
- 2019-Under 40 Award from the Ohio Pharmacists Association
- 2020-Diabetes Care and Education Specialist from the Association of Diabetes Care and Education Specialists (ADCES)
- 2020-Fellow of the American College of Clinical Pharmacy (FCCP)
- 2020-Fellow of ADCES (FADCES)
Recent Photos
AJMC Institute of
Pregnancy Program
Cleveland Clinic

ADCES Conference

AMCP Nexus Conference

ADA 83rd
Scientific Sessions
ADA 83rd
Scientific Sessions




AJMC Institute of
Pregnancy Program
Cleveland Clinic
ADCES Conference
AMCP
Nexus Conference
ADA 83rd
Scientific Sessions




Select Professional Activities
American Association of Clinical Endocrinology
- GLP-1 Program Planning Committee: 2024-Present
- Annual Meeting Scientific Committee: 2024-Present
- Certificate Programs Committee: 2023-Present
- Awards Committee: 2024-Present
- Endocrine Care Team Steering Committee Vice Chair: 2024-Present
- Nominations Committee: 2022-2023
- Clinical Practice Guideline Oversight Committee: 2021-2023
- Cardiometabolic Conference Planning Committee: 2022
- CGM Data Interpretation/Application Project Committee: 2021
- Diabetes Disease State Network
- Vice Chair, Diabetes Resource 2022-2023
- Vice Chair, Diabetes Education Programming: 2023-Present
- Obesity Disease State Network: 2021-Present
- National Board Member: 2022-2024
- Performance Oversight and Monitoring Committee: 2023
- Planning and Development Committee: 2022
- Chair, Stakeholder and Member Relations Committee: 2024
- Governance Committee: 2024
- Technology Conference Planning Committee Chair: 2021-Present
- Pharmacy Community of Interest Chair: 2018
- Ohio ADCES Coordinating Body President: 2018-2023 Chair: 2018-2023
- Coordinating Body Present-Elect: 2017
- Board of Directors: 2016-Present
- ADCES Spokesperson: 2019-2022
- Integrated Diabetes Fellowship Committee: 2020-2021
- Technology Committee: 2019-2021
- ADA Resources Advisory Panel: 2024
- Time in Range Advisory Group: 2021-2023
- Scientific Sessions Planning Committee: 2022-2023
- Lead Technology Planning: 2023
- Scientific Sessions Subcommittee: 2020, 2024
- Professional Practice Committee (updates ADA Standards of Care): 2020-2022
- Communications Director: Pregnancy & amp; Reproductive Health Interest Group: 2018-2022
- Scientific and Medical Programs Oversight Committee: 2024-Present
- Task Force Artificial Intelligence in Healthcare: 2023-2024
- Task Force on Treatment Guidelines: 2021-2022
- Task Force Telehealth and Technology: 2019-2020
- Member Relations Committee: 2020-2021
- Endocrine and Metabolism Practice Research Network (PRN): 2010-Present
- Nominations Committee: 2020-2022
- Nominations Committee chair: 2021
- Chair-Elect: 2018-2019
- Healthcare Committee: 2017-2018
- Ambulatory Care Practice Network (PRN):2009-Present
- Budget and Finance Committee: 2021-2022
- Communications Committee Vice-Chair: 2019-2020
- Research Committee: 2016-2019
- Ambulatory Care Section Clinical Advancement Advisory Group: 2023-2024
- Ambulatory Care Section Educational Steering committee: 2014-2022
- Vice Chair: 2019-2020
- Chair: 2020-2021
- CGM Advisory Board: 2023
- Academy of Pharmacy Practice and Management (APPM) Education Committee, 2017-2018, 2021-2022
- USP Insulin Roundtable Representative: 2020
- DSMES Paper Review Committee Chair: 2020
- Diabetes SIG Student Committee Chair-Elect: 2016-2017
- Diabetes SIG Student Committee Chair: 2017-2018
- Credentials Committee, 2018-Present
X Feed
What's new in diabetes technology?
Tune into the latest #DiabetesDialogue to learn about a pair of trials examining insulin delivery systems in adults with #Type2Diabetes.
@DianaMIsaacs @natalie_bellini
https://www.hcplive.com/view/diabetes-dialogue-omnipod-5-and-medtronic-780g-for-type-2-diabetes
📣 Perspective from @DianaMIsaacs:
"This confirms what we see in practice that Omnipod 5 (and other automated insulin delivery systems) work very well for people with type 2 #diabetes that need insulin."
@GoHealio
https://www.healio.com/news/endocrinology/20250214/automated-insulin-delivery-lowers-hba1c-improves-time-in-range-in-type-2-diabetes#EFE71645510B41F78A3E741F631A3635
Great news for people with T2D and CKD!
The FLOW trial was stopped early due to clear benefits for using semaglutide to reduce progression of kidney disease and cardiovascular death in people with #T2D at risk for progressive diabetic kidney disease @US_FDA @novonordiskus